What is CG Oncology's goodwill?

CG Oncology (CGON) reported goodwill of $10.3M in Q1 2026.

What does goodwill mean?

The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.

CG Oncology CGON Goodwill

Goodwill at other companies

PfizerPFE

$71.41B+4.3%

Johnson & JohnsonJNJ

$48.56B+9.2%

Gilead SciencesGILD

$8.31B0.0%

ImmunityBio, Inc.IBRX

$910K0.0%

Summit TherapeuticsSMMT

$1.97M+2.2%

ExelixisEXEL

$63.68M0.0%

Other financials

Income statement

See full

Revenue$1.1M+1,983%

Operating income-$66.4M-57.3%

Net income-$60.2M-74.7%

EPS (diluted)-$0.71-57.8%

Balance sheet

See full

Cash & equivalents$33.7M-18.7%

Total debt$7.6M+631%

Total equity$1.1B+54.9%

Total assets$1.1B+55.9%

Cash flow

See full

Operating cash flow-$56.9M-94.5%

CapEx$304.0K+1,800%

Free cash flow-$57.2M-95.4%

Valuation

See full

Market cap$5.8B+206%

Profitability

See full

Operating margin-4,239%-1,872pp

Net margin-3,682.6%-1,601pp

FCF margin-3,163.8%-1,351pp

Returns & leverage

See full

Return on equity-20.8%+7.1pp

Debt / equity0×0.0×

Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CG Oncology's goodwill?: CG Oncology (CGON) reported goodwill of $10.3M in Q1 2026.
What does goodwill mean?: The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.